Quality of life with cemiplimab plus chemotherapy for first‐line treatment of advanced non–small cell lung cancer: Patient‐reported outcomes from phase 3 EMPOWER‐Lung 3

Tamta Makharadze; Ruben G.W. Quek; Tamar Melkadze; Miranda Gogishvili; Cristina Ivanescu; Davit Giorgadze; Mikhail Dvorkin; Konstantin Penkov; К. К. Лактионов; Gia Nemsadze; Marina Nechaeva; Irina Rozhkova; Ewa Kalinka‐Warzocha; Christian Geßner; Brizio Moreno‐Jaime; Rodolfo Passalacqua; Gerasimos Konidaris; Petra Rietschel; Giuseppe Gullo

doi:10.1002/cncr.34687

Abstract

This is the authors' abstract. We don't add key points for this paper.

Cemiplimab plus chemotherapy resulted in significant overall improvement in pain symptoms and delayed TTD in cancer-related and lung cancer-specific symptoms and functions.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Makharadze et al. (2023) studied this question.

synapsesocial.com/papers/69d91c26f20ef263306841b6 https://doi.org/10.1002/cncr.34687

View Full Paper

Ask AI

Bookmark

Abstract

This is the authors' abstract. We don't add key points for this paper.

Cemiplimab plus chemotherapy resulted in significant overall improvement in pain symptoms and delayed TTD in cancer-related and lung cancer-specific symptoms and functions.

Quality of life with cemiplimab plus chemotherapy for first‐line treatment of advanced non–small cell lung cancer: Patient‐reported outcomes from phase 3 EMPOWER‐Lung 3

Abstract

Ask about this paper

Discussion

Cite This Study

Quality of life with cemiplimab plus chemotherapy for first‐line treatment of advanced non–small cell lung cancer: Patient‐reported outcomes from phase 3 EMPOWER‐Lung 3

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading